US equities
|
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
SPCX
$148.58
▲+0.00%
STX
$667.85
▲+0.00%
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
SPCX
$148.58
▲+0.00%
STX
$667.85
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Structure Therapeutics Inc. - American Depositary Shares
(NQ:
GPCR
)
21.55
UNCHANGED
Delayed Quote
Updated: 4:15 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Structure Therapeutics Inc. - American Depositary Shares
< Previous
1
2
3
Next >
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
October 19, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
September 08, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 03, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
June 05, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 07, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
April 27, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
April 14, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
March 16, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
February 26, 2026
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
December 17, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
December 11, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
December 09, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 08, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 07, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
September 02, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
August 18, 2025
Via
AB Newswire
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 06, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
May 29, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
May 08, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
February 27, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
January 30, 2025
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
December 17, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
November 15, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
November 13, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
November 13, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
October 31, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
